Vancomycin treatment induced an increase of systemic CD8α+ DCs, tumor-associated antigen cross-priming with antitumor CD8+ T cell elicitation, and tumor growth inhibition in mice, via decreasing SCFAs (121, 122). The gene discussed is CD8A; the disease is neoplasm.